UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Psomagen seeks KOSDAQ listing using technology exception policy
Psomagen, a U.S. subsidiary of Macrogen, said it would use Korea’s “technol...
by Jeong Sae-im
|
2019-07-10 15:20
라인
Kolon files administrative suit against Invossa license revocation
Kolon Life Science said it has filed an administrative lawsuit against the ...
by Jeong Sae-im
|
2019-07-09 11:47
라인
SillaJen shareholders panic over exec’s selling of 160,000 stocks
An executive at SillaJen suddenly sold 160,000 shares for “personal reasons...
by Jeong Sae-im
|
2019-07-09 11:45
라인
Kolon TissueGene’s ₩490 billion shares on verge of becoming worthless
The stock market operator said it would review whether to keep Kolon Tissue...
by Jeong Sae-im
|
2019-07-08 12:06
라인
Victims question Kolon CEO’s sincerity in apology
Oh Kims Law & Co., leading a lawsuit against Kolon Life Science on behalf o...
by Jeong Sae-im
|
2019-07-05 15:14
라인
Samsung, Genentech settle patent dispute on Herceptin biosimilar
Samsung Bioepis has settled a patent infringement case with Genentech, a su...
by Lee Han-soo
|
2019-07-05 11:47
라인
Kolon confident to resume US trial on Invossa
The government has decided to nullify Invossa-K’s license effective next Tu...
by Lee Hye-seon
|
2019-07-04 14:05
라인
China OKs Alteogen’s Herceptin biosimilar for clinical trials
Alteogen said that Qilu Pharmaceutical, its Chinese partner, has received i...
by Lee Han-soo
|
2019-07-04 14:04
라인
Regulator revokes Invossa license; Kolon CEO ‘to fight in court’
Kolon Life Science CEO said he would seek an administrative suit against th...
by Lee Hye-seon
|
2019-07-03 11:52
라인
BNO BIO to invest $1 million in Israeli biotech venture
BNO BIO, a joint venture between Bukwang Pharm and chemical and energy comp...
by Jeong Sae-im
|
2019-06-28 16:10
라인
Shareholders in shock over HLB’s phase-3 trial setback
Investors in HLB have expressed shock after the KOSDAQ-listed firm announce...
by Jeong Sae-im
|
2019-06-28 10:47
라인
‘Food and drug ministry alone can’t handle Invossa debacle’
“The National Medical Center (NMC), the Korea Centers for Disease Control a...
by Jeong Sae-im
|
2019-06-27 12:45
라인
Oscotech wins exception policy for continued R&D for new drugs
The stock market regulator granted Oscotech to become the third KOSDAQ-list...
by Jeong Sae-im
|
2019-06-25 14:11
라인
Despite regulator’s ruling delay, Kolon TissueGene likely to be reviewed for delisting
The stock market regulator said it has pushed back the deadline to decide w...
by Jeong Sae-im
|
2019-06-20 14:20
라인
294 shareholders file suit against Kolon TissueGene for damage compensation
Kolon TissueGene said in a public filing on Thursday that its 294 minority ...
by Jeong Sae-im
|
2019-06-14 10:51
라인
Celltrion unveils P3 trial results for rheumatoid biosimilar in Europe
Celltrion has presented the phase 3 clinical trial result for Remsima SC, t...
by Lee Han-soo
|
2019-06-13 16:10
라인
Kolon TissueGene CEO resigns
Kolon TissueGene, a subsidiary of Kolon Life Science, said Co-CEO Lee Woo-s...
by Jeong Sae-im
|
2019-06-07 15:35
라인
[ASCO 2019] ‘Ontruzant demonstrates equal quality to original drug’
CHICAGO, Ill. -- Samsung Bioepis has proved its quality control ability, as...
by Lee Han-soo, KBR correspondent
|
2019-06-04 14:17
라인
Kolon’s minority shareholders demand over ₩25 billion in damage
Minority shareholders of Kolon Life Science and its subsidiary Kolon Tissue...
by Jeong Sae-im
|
2019-06-03 14:53
라인
Invossa inventor sold Kolon shares at highest value
Former Kolon TissueGene CEO Lee Kwan-hee, the inventor of now-suspended gen...
by Jeong Sae-im
|
2019-06-03 14:52
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top